Currently out of the existing stock ratings of Kennen Mackay, 130 are a BUY (65.66%), 66 are a HOLD (33.33%), 2 are a SELL (1.01%).

Kennen Mackay

Work Performance Price Targets & Ratings Chart

Analyst Kennen Mackay works with a stock forecast success ratio of 52.69% fulfilled within 139.12 days on average. Previously, Kennen Mackay worked at RBC.

Kennen Mackay’s has documented 378 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VIRX, Viracta Therapeutics at 10-Nov-2023.

Wall Street Analyst Kennen Mackay

Analyst best performing recommendations are on XLRN (ACCELERON PHARMA).
The best stock recommendation documented was for SGEN (SEAGEN) at 2/1/2021. The price target of $186 was fulfilled within 4 days with a profit of $23.14 (14.21%) receiving and performance score of 35.52.

Average potential price target upside

ABEO Abeona Therapeutics AGIO Agios Pharm AIMT Aimmune Therapeutics AKBA Akebia Ther ALXN Alexion Pharmaceuticals AMGN Amgen ANAB AnaptysBio ARNA Arena Pharmaceuticals ATNX Athenex BMRN Biomarin Pharmaceutical CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics GMAB Genmab AS IMGN ImmunoGen OBSV ObsEva SA ONCE Spark Therapeutics PBYI Puma Biotechnology PRTA Prothena plc REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma ADCT ADC Therapeutics SA NUVB Nuvation Bio LIFE aTyr Pharma VIRX Viracta Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

6

$-1.52 (-20.21%)

5

1 years 5 months 8 days ago

2/3 (66.67%)

$1.85 (44.58%)

257

Buy

15

1 years 5 months 14 days ago

1/2 (50%)

$10.34 (221.89%)

61

Buy

2 years 4 months 24 days ago

0/1 (0%)

$332.5 (79.64%)

Buy

75

$70.79 (1681.47%)

50

3 years 5 months 11 days ago

2/3 (66.67%)

$45.92 (117.11%)

101

Buy

22

3 years 11 months 14 days ago

1/3 (33.33%)

$-59.25 (-72.92%)

820

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kennen Mackay is most bullish on?

Potential upside of $0.77 has been obtained for NUVB (NUVATION BIO)

Which stock is Kennen Mackay is most reserved on?

Potential downside of -$13.2 has been obtained for AMGN (AMGEN)

What Year was the first public recommendation made by Kennen Mackay?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?